Table 2.

Details of the 26 patients with neoadjuvant ICB therapy.

Patient	Sex	Age	Tumor location	Clinical TNM stage	Invaded organ	ICB	Courses of ICB	Neoadjuvant chemotheropy	Tumor response	Surgery	Pathological stage	TRG
1	Male	60	Colon	cT4bN1M0	Adjacent colon	Envafolimab	8	NA	MPR	CME	ypT0N1	1
2	Female	78	Colon	cT4bN1M0	Bladder	Tislelizumab	1	NA	PR	CME+partial cystectomy	ypT3N0	2
3	Male	47	Colon	cT4aN1M0	NA	Sintilimab	3	NA	pCR	CME	ypT0N0	0
4	Male	58	Colon	cT4aN0M0	NA	Pembrolizumab	3	NA	pCR	CME	ypT0N0	0
5	Male	66	Colon	cT4bN0M0	Small intestine	Tislelizumab	3	NA	pCR	CME+partial small bowel resection	ypT0N0	0
6	Female	69	Colon	cT3N0M0	NA	Tislelizumab	3	NA	pCR	CME	ypT0N0	0
7	Male	49	Colon	cT4aN0M0	NA	Tislelizumab	3	NA	pCR	CME	ypT0N0	0
8	Female	37	Colon	cT4aN1M0	NA	Pembrolizumab	6	NA	pCR	CME	ypT0N0	0
9	Male	74	Rectum	cT3N0M0	NA	Envafolimab	2	XELOX × 2	pCR	PME	ypT0N0	0
10	Female	41	Colon	cT3N2M0	NA	Tislelizumab	6	XELOX × 6	pCR	CME	ypT0N0	0
11	Male	37	Colon	cT3N0M0	NA	Nivolumab	6	XELOX × 2 Pre ICB	pCR	CME	ypT0N0	0
12	Female	58	Colon	cT3N2M0	NA	Envafolimab	4	NA	pCR	CME	ypT0N0	0
13	Male	46	Colon	cT3N2M0	NA	Sintilimab	2	XELOX × 1 Pre ICB	pCR	CME	ypT0N0	0
14	Male	74	Colon	cT3N2M0	NA	Sintilimab	7	XELOX × 3 Pre ICB	pCR	CME	ypT0N0	0
15	Female	43	Colon	cT4aN2M0	NA	Tislelizumab	4	NA	pCR	CME	ypT0N0	0
16	Male	61	Colon	cT4N1M0	NA	Tislelizumab	3	NA	pCR	CME	ypT0N0	0
17	Male	37	Colon	cT4aN1M0	NA	Tislelizumab	4	XELOX × 4	pCR	CME	ypT0N0	0
18	Female	47	Colon	cT4bN1M0	Bladder	Envafolimab	2	XELOX × 2	pCR	CME	ypT0N0	0
19	Female	70	Colon	cT4aN1M0	NA	Tislelizumab	2	NA	pCR	CME	ypT0N0	0
20	Male	49	Colon	cT3N0M0	NA	Pembrolizumab	5	NA	pCR	CME	ypT0N0	0
21	Male	33	Colon	cT3N1M0	NA	Envafolimab	4	NA	pCR	CME	ypT0N0	0
22	Female	75	Colon	cT3N1M0	NA	Tislelizumab	4	NA	pCR	CME	ypT0N0	0
23	Male	64	Colon	cT4bN1M0	Ureter	Sintilimab	4	FOLFOX × 4	pCR	CME	ypT0N0	0
24	Male	60	Rectum	cT3N1M0	NA	Sintilimab	2	FOLFOX × 2	pCR	PME	ypT0N0	0
25	Male	60	Colon	cT4aN1M0	NA	Envafolimab	8	NA	pCR	CME	ypT0N0	0
26	Male	52	Colon	cT3N0M0	NA	Envafolimab	9	NA	pCR	CME	ypT0N0	0

ICB, immune checkpoint blockade; TRG, tumor regression grade; NA, not available; MPR, major pathological response; PR, partial response; pCR, pathological complete response; CME, complete mesocolic excision; PME: partial mesorectal excision.